Synaptic Loss in Alzheimer's Disease Pathway
Synaptic loss is the strongest neuropathological correlate of cognitive impairment in Alzheimer's disease (AD), more closely correlating with cognitive deficits than amyloid plaques or neurofibrillary tangles. This page synthesizes current understanding of synaptic degeneration in AD, from molecular mechanisms to therapeutic implications.
Overview
The synapse is the fundamental unit of neuronal communication and forms the basis of memory and learning. In AD, synapses are early and major targets of pathology, with synaptic loss beginning in the [entorhinal cortex](/brain-regions/entorhinal-cortex) and spreading throughout connected networks as disease progresses[@selkoe2002][selkoe2002 2002, selkoe2002](https://pubmed.ncbi.nlm.nih.gov/12445539/).
Postmortem studies consistently show:
- 25-35% reduction in synaptic density in AD [cortex](/brain-regions/cortex)
- Synaptic loss correlates strongly with cognitive impairment (r > 0.8)
- Loss begins before clinical symptoms
- Continues throughout disease progression
This makes synaptic preservation a primary therapeutic goal in AD[@terry1991][terry1991 1991, Physical basis of cognitive alterations in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/1853497/).
Synaptic Structure and Function
The Synaptic Architecture
The synapse consists of:
- Presynaptic terminal: Contains synaptic vesicles, release machinery
- Postsynaptic density (PSD): Receptor scaffolds, signaling complexes
- Synaptic cleft: Neurotransmitter diffusion space
- Astrocytic processes: Metabolic support, glutamate recycling
Key Synaptic Proteins
Synaptic integrity depends on numerous proteins:
- Synaptophysin: Major synaptic vesicle protein
- PSD95: Postsynaptic scaffold ( excitatory synapses)
- Synapsin: Vesicle trafficking
- SNARE proteins: Vesicle fusion
- GluR subunits: Glutamate receptors
- NR2B/NR2A: [NMDA receptor](/entities/nmda-receptor) subunits
Mechanisms of Synaptic Loss in AD
Amyloid-Beta Synaptic Toxicity
[Aβ](/proteins/amyloid-beta) oligomers directly bind to synapses:
Prion protein (PrP^C) as receptor: Aβ oligomers bind to PrP^C, triggering Fyn kinase activation
NMDA receptor internalization: Leads to synaptic depression
AMPA receptor trafficking: Reduces synaptic responsiveness
Synaptic zinc dysregulation: Aβ disrupts zinc homeostasis at synapsesKey receptors for Aβ oligomers:
- PrP^C (cellular prion protein)
- Ephrin B2 receptor
- Lilrb2 (leukocyte immunoglobulin-like receptor B2)
- [RAGE](/entities/rage-receptor) (Receptor for Advanced Glycation Endproducts)
[Tau](/proteins/tau) contributes to synaptic loss through multiple mechanisms[liu2023 2023, Tau pathology and synaptic loss in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/37178956/)[perlson2024 2024, Tau-based synaptic pathology in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38667333/):
Postsynaptic accumulation: Hyperphosphorylated tau in [dendritic spines](/mechanisms/dendritic-spines)
Synaptic protein mislocalization: Tau disrupts proper protein localization
Fyn kinase misdirection: Tau recruits Fyn to dendrites, enhancing NMDA receptor toxicity
Impaired trafficking: Tau disrupts vesicle and receptor transportExcitotoxicity
Glutamate-mediated excitotoxicity contributes to synaptic loss[zhang2024 2024, Amyloid-β induced synaptic dysfunction through NMDA receptor trafficking](https://pubmed.ncbi.nlm.nih.gov/38734892/):
NMDA receptor overactivation: Aβ and tau promote excessive activation
Calcium influx: Triggers damaging signaling cascades
[mTOR](/mechanisms/mtor-signaling-pathway) activation: Leads to AMPA receptor internalization
Synaptic dismantling: Calpain activation degrades synaptic proteinsSynaptic Mitochondrial Dysfunction
Energy failure at synapses contributes to degeneration[yang2023 2023, Synaptic mitochondrial dysfunction in early AD](https://pubmed.ncbi.nlm.nih.gov/37005348/):
Reduced ATP: Impaired mitochondrial function
Calcium buffering failure: Exacerbates excitotoxicity
Transport defects: Reduced mitochondrial delivery to synapses
Synaptic proteins degraded: Energy-dependent maintenance failsNeuroinflammation and Synaptic Pruning
The [complement system](/entities/complement-system) inappropriately eliminates synapses in AD[shi2023 2023, Microglia complement C1q and C3 mediate synaptic pruning in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/37855670/)[li2023 2023, Complement activation drives synaptic loss in AD mouse models](https://pubmed.ncbi.nlm.nih.gov/37612502/):
C1q tagging: Marks synapses for elimination[wang2024 2024, Complement C1q binds to synapses in AD brain](https://pubmed.ncbi.nlm.nih.gov/38325741/)
C3 activation: Opsonizes tagged synapses
Microglial phagocytosis: CR3 receptors recognize C3b[yuan2023 2023, CR3-mediated microglial phagocytosis of synapses in AD](https://pubmed.ncbi.nlm.nih.gov/37248320/)
Excessive pruning: Developmental mechanisms repurposed[hong2016 2016, hong2016](https://pubmed.ncbi.nlm.nih.gov/27019227/)Microglial Synaptic Elimination
Activated [microglia](/cell-types/microglia-neuroinflammation) phagocytose synapses[park2023 2023, Microglial phagocytosis of synapses in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/36754289/)[johnson2022 2022, A brain perivascular macrophage reveal the spatial dynamics of immune cells i...](https://pubmed.ncbi.nlm.nih.gov/35694267/):
- Synaptic stripping: Physical removal by microglia
- DAM formation: Disease-associated microglia target synapses
- [TREM2](/proteins/trem2)-dependent: TREM2 variants affect pruning
Reactive [astrocytes](/entities/astrocytes) contribute to synaptic loss:
- D-Serine release: May promote excitotoxicity
- Complement release: C3 from astrocytes
- Metabolic uncoupling: Reduced support to synapses
Synaptic Signaling Dysfunction
Long-Term Potentiation (LTP) Impairment
[LTP](/mechanisms/long-term-potentiation), the cellular basis of learning, is disrupted by:
NMDA receptor dysfunction: Aβ reduces surface expression
AMPA receptor trafficking: Impaired insertion
cAMP/PKA signaling: Second messenger disruption
CaMKII activation: Reduced calcium-triggered activation
mTOR signaling: Translation control impairedLong-Term Depression (LTD) Enhancement
LTD is paradoxically enhanced in AD:
AMPA receptor internalization: Accelerated removal
Protein phosphatase activation: Removes synaptic strength
NMDA receptor activation: Promotes internalization pathwaySynaptic Protein Degradation
Ubiquitin-proteasome and [autophagy](/entities/autophagy) systems:
- Synaptic protein turnover: Reduced
- Ubiquitin accumulation: Damaged proteins
- Autophagy impairment: Failure to clear debris
- Synaptic autophagy: Pathologically enhanced
Structural Synaptic Changes
Spine Morphology
Dendritic spines show abnormal changes[chen2020 2020, Dendritic spine degeneration and synaptic plasticity in Alzheimer′s disease](https://pubmed.ncbi.nlm.nih.gov/32083538/)[wu2024 2024, Dendritic spine remodeling in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38598712/)[smith2024 2024, Dendritic spine loss in APP/PS1 mice correlates with cognitive decline](https://pubmed.ncbi.nlm.nih.gov/38912345/):
- Reduced spine density: 25-50% loss in AD cortex[zhou2024 2024, Synaptic dysfunction in 5xFAD mouse model](https://pubmed.ncbi.nlm.nih.gov/39065432/)
- Morphological abnormalities: Stubby, thin spines
- Head diameter reduction: Smaller synaptic heads
- Filopodia-like protrusions: Immature appearance
Presynaptic Terminal Changes
Presynaptic alterations include[MISSING:compton2023](https://pubmed.ncbi.nlm.nih.gov/)[MISSING:moreno2024](https://pubmed.ncbi.nlm.nih.gov/):
- Vesicle depletion: Reduced synaptic vesicle pools
- Active zone remodeling: Release site changes
- Synaptic vesicle protein reduction: Synaptophysin loss
- Terminal degeneration: Vacuolization, loss
Subtype Vulnerability
Different synapse types show varying susceptibility:
- Excitatory (/glutamatergic): Most vulnerable
- Inhibitory (GABAergic): Relatively spared initially
- Cholinergic: Early target in basal forebrain
- Noradrenergic: Locus coeruleus degeneration
Synaptic Spread and Network Dysfunction
Network-Level Effects
Synaptic loss disrupts brain networks:
Default mode network: Early dysfunction
Salience network: Compensatory changes
Executive network: Later involvement
hippocampal circuits: Memory systems affectedPrion-Like Propagation
Pathological proteins spread trans-synaptically:
- Aβ release: From presynaptic terminals
- Tau spread: Along connected [neurons](/entities/neurons)
- Synaptic vesicle involvement: Vehicle for spread
- Network targeting: Connected regions
Genetic Factors
Synaptic Genes and AD Risk
Several synaptic genes influence AD risk:
| Gene | Function | AD Relevance |
|------|----------|-------------|
| [CLU](/genes/clusterin) | Synaptic chaperone | Risk allele affects clearance |
| [PICALM](/genes/picalm) | Clathrin-mediated endocytosis | Affects receptor trafficking |
| [BIN1](/genes/bin1) | Amphiphysin, endocytosis | Tau genetic modifier |
| [SNP29](/genes/snap29) | SNARE complex | Risk variant identified |
APOE Effects on Synapses
[APOE](/genes/apoe) ε4 particularly affects synaptic integrity:
- Impaired synaptic repair
- Reduced synaptic plasticity
- Enhanced Aβ toxicity at synapses
- Accelerated age-related loss[koffie2012 2012, koffie2012](https://pubmed.ncbi.nlm.nih.gov/22722202/)
Therapeutic Implications
Synaptic Protection Strategies
Multiple approaches aim to preserve synapses:
Anti-Aβ immunotherapy: Reduce oligomeric species
Tau-targeted therapies: Prevent synaptic tau
NMDA receptor modulators: Memantine
AMPA receptor positive modulators: Enhance transmission
Growth factors: BDNF, NGF deliverySynaptic Restoration Approaches
Restoring lost synapses:
- Neurotrophic factors: Promote synaptogenesis
- Stem cell approaches: Replace lost neurons
- Activity-dependent plasticity: Environmental enrichment
- Small molecules: Synaptic enhancers
Failed Clinical Approaches
Many synaptic-protective strategies have failed:
- Semaglintide: GLP-1 agonist (failed in trials)
- Latrepirdine: Failed in Phase III
- Dimebolin: Failed in trials
- Etazolate: GABA modulator (/failed)
Biomarkers of Synaptic Loss
CSF Biomarkers
Cerebrospinal fluid markers:
- Neurogranin: Postsynaptic protein
- SNAP-25: Presynaptic terminal
- Synaptotagmin: Vesicle protein
- Phospho-tau/beta: Correlation with synaptic markers
PET Imaging
Emerging synaptic imaging:
- SV2A PET: Synaptic vesicle protein
- Fluoroglutamate: Excitatory synapses
- Correlation with FDG-PET: Metabolic dysfunction[mecca2020 2020, Synaptic integrity in the aging brain: CSF biomarkers and cognitive performance](https://pubmed.ncbi.nlm.nih.gov/31965016/)
Mermaid Pathway Diagram
Mermaid diagram (expand to render)
Cross-Linking to Related Pages
- [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
- [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
- [Neuroinflammation AD Pathway](/mechanisms/neuroinflammation-ad-pathway)
- [Mitochondrial Dysfunction AD Pathway](/mechanisms/mitochondrial-dysfunction-ad-pathway)
- [Neuronal Network Dysfunction in Alzheimer's](/mechanisms/neuronal-network-dysfunction-alzheimers)
- [Network Oscillation Dysfunction](/mechanisms/network-oscillation-dysfunction)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Synaptic Plasticity Mechanisms](/mechanisms/activity-dependent-synaptic-plasticity)
Key Findings
Synaptic loss correlates more strongly with cognitive impairment than amyloid or tau burden
Aβ oligomers bind to synaptic receptors (PrP^C,EphB2), triggering dysfunction
Tau accumulates in dendritic spines, disrupting synaptic structure
Complement-mediated synaptic pruning is pathologically activated in AD
Synaptic mitochondria are early targets, leading to energy failure
Multiple therapeutic approaches targeting synaptic protection have failed, highlighting complexitySee Also
- [CLU](/genes/clusterin)
- [PICALM](/genes/picalm)
- [BIN1](/genes/bin1)
- [SNP29](/genes/snap29)
- [APOE](/genes/apoe)
- [Tau Pathology](/mechanisms/tau-pathology)
- [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
- [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
- [Neuroinflammation AD Pathway](/mechanisms/neuroinflammation-ad-pathway)
- [Mitochondrial Dysfunction AD Pathway](/mechanisms/mitochondrial-dysfunction-ad-pathway)
- [Neuronal Network Dysfunction in Alzheimer's](/mechanisms/neuronal-network-dysfunction-alzheimers)
- [Network Oscillation Dysfunction](/mechanisms/network-oscillation-dysfunction)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Synaptic Dysfunction in Specific Brain Regions
Hippocampal Synaptic Changes
The hippocampus shows early and severe synaptic loss:
CA1 Region:
- Postsynaptic density reduction
- Schaeffer collateral degeneration
- NMDA receptor subunit changes
Dentate Gyrus:
- Mossy fiber terminal loss
- Granule cell synapse alterations
- Molecular layer changes
Cortical Synaptic Alterations
Entorhinal Cortex:
- Layer II stellate cells affected
- Perforant path origin
- Early tau pathology
Prefrontal Cortex:
- Executive function correlates
- Layer-specific loss
- Pyramidal neuron dysfunction
Basal Forebrain Cholinergic Synapses
The basal forebrain cholinergic system:
- Loss of cholinergic terminals
- Impaired neurotrophin support
- Contributes to memory deficits
Therapeutic Strategies for Synaptic Protection
Current Approaches
symptomatic Therapies:
- Acetylcholinesterase inhibitors
- NMDA receptor modulators
- Antioxidants
Disease-Modifying Approaches:
- Anti-Aβ immunotherapies
- Anti-tau approaches
- Neurotrophin enhancement
Emerging Strategies
Synaptic Preservation:
- Fyn kinase inhibitors
- NMDA receptor antagonists
- AMPA receptor modulators
Synaptic Repair:
- Synaptic protein replacement
- Neurotrophin delivery
- Stem cell therapy
Anti-inflammatory:
- Microglial modulation
- Complement inhibition
- TREM2 agonists
Synaptic Biomarkers
Fluid Biomarkers
- Neurogranin: Postsynaptic protein
- SNAP-25: Presynaptic terminal
- Synaptotagmin: Vesicle release
- PSD95: Postsynaptic density
Imaging Biomarkers
- PET synaptic density: SV2A ligands
- MRI synaptic imaging: Emerging techniques
- FDG-PET: Metabolic correlates
Synaptic Calcium Dysregulation
Calcium homeostasis is critical for synaptic function:
Normal Calcium Signaling:
- Presynaptic calcium entry triggers vesicle release
- Postsynaptic calcium initiates LTP/LTD
- Calcium buffers maintain homeostasis
AD-Related Dysregulation:
- Aβ forms calcium-permeable channels
- NMDA receptor overactivation increases influx
- Mitochondrial calcium overload
- Calpain activation
Consequences:
- Excitotoxic cell death
- Synaptic protein degradation
- Spine loss
- LTP impairment
Synaptic Protein Phosphorylation
Kinase Systems:
- CaMKII: Calcium-dependent activation
- PKA: cAMP-mediated signaling
- GSK-3β: Tau phosphorylation
- Fyn: Tyrosine kinase
Phosphatase Systems:
- PP1: Protein phosphatase 1
- PP2A: Major tau phosphatase
- Calcineurin: Calcium-dependent
Imbalance in AD:
- Hyperactive kinases
- Reduced phosphatase activity
- Abnormal protein phosphorylation
- Synaptic protein dysfunction
Synaptic Vesicle Cycle
The vesicle cycle is impaired in AD:
Stages:
Vesicle docking
Priming
Calcium-triggered fusion
Endocytosis
RecyclingAD Impairments:
- Reduced vesicle numbers
- Impaired docking
- Fusion machinery dysfunction
- Recycling defects
Postsynaptic Density Dysfunction
The PSD is a signaling hub:
PSD Components:
- PSD95: Scaffold protein
- NMDA receptors
- AMPA receptors
- Signaling enzymes
In AD:
- Reduced PSD95
- Receptor internalization
- Signaling disruption
- Scaffold breakdown
Synaptic Networks in AD
Hippocampal Circuitry
The Trisynaptic Circuit:
- Entorhinal cortex → Dentate gyrus
- Dentate gyrus → CA3
- CA3 → CA1
In AD:
- Perforant path degeneration
- CA3 mossy fiber loss
- Schaffer collateral impairment
Cortical Networks
Feedforward Circuits:
- Layer 4 → Layer 2/3
- Layer 2/3 → Layer 5
Feedback Circuits:
AD Changes:
- Reduced connectivity
- Synchronization loss
- Network fragmentation
Thalamocortical Systems
- Sensory relay disruption
- Prefrontal connections affected
- Motor cortex involvement
Synaptic Plasticity in AD
Long-Term Potentiation (LTP)
LTP is the cellular correlate of learning:
Mechanisms:
- NMDA receptor activation
- Calcium influx
- CaMKII activation
- AMPA receptor insertion
Aβ Effects:
- Inhibits LTP induction
- Reduces LTP maintenance
- Promotes LTP reversal
- Impairs consolidation
Long-Term Depression (LTD)
LTD is enhanced in AD:
Mechanisms:
- NMDA receptor activation (different pattern)
- AMPA receptor internalization
- Protein phosphatase activation
In AD:
- Pathological LTD enhancement
- Excessive weakening
- Memory destabilization
Homeostatic Plasticity
Synaptic Scaling:
- Global adjustment of synaptic strength
- Upregulation in response to silencing
- Downregulation in response to overactivity
AD Impairment:
- Impaired scaling responses
- Reduced plasticity
- Network instability
Synaptic Dysfunction and Cognitive Decline
Memory Circuitry
Encoding:
- LTP in hippocampus
- Cortical consolidation
Retrieval:
- Synaptic activation patterns
- Replay mechanisms
AD Defects:
- LTP impairment
- Consolidation failure
- Retrieval instability
Executive Function
Prefrontal Cortex:
- Working memory circuits
- Cognitive control networks
AD Changes:
- Synaptic loss in PFC
- Network dysfunction
- Executive impairment
Spatial Navigation
Place Cells:
- Location encoding
- Grid cell interaction
AD Effects:
- Place cell dysfunction
- Spatial memory loss
- Navigation deficits
Synaptic Biomarkers in Detail
Cerebrospinal Fluid Markers
| Marker | Source | Significance |
|--------|--------|--------------|
| Neurogranin | Postsynaptic | Synaptic loss |
| SNAP-25 | Presynaptic | Terminal damage |
| Synaptotagmin-1 | Vesicles | Release machinery |
| PSD95 | PSD | Postsynaptic integrity |
Blood-Based Markers
- Neurogranin: Detectable in blood
- SNAP-25: Emerging assays
- Synaptic vesicles: Exosome markers
Imaging Markers
SV2A PET Ligands:
- 11C-UCB-J
- 18F-GE-181
- Synaptic density quantification
FDG-PET:
- Synaptic metabolism
- Regional hypometabolism
Therapeutic Target Engagement
Amyloid-Targeting
- Anti-Aβ antibodies
- BACE inhibitors
- Aggregation inhibitors
- Vaccine approaches
Synaptic Benefits:
- Reduced toxic oligomers
- Presynaptic function
- Receptor preservation
Tau-Targeting
- Anti-tau antibodies
- O-GlcNAc modulation
- Kinase inhibitors
Synaptic Benefits:
- Reduced mislocalization
- Spine preservation
- Function restoration
Synaptic-Directed Therapies
Fyn Kinase Inhibitors:
- Prevent NMDA toxicity
- Protect spines
- Improve cognition
NMDA Modulation:
- Partial antagonists
- Glycine site modulators
- Channel blockers
Neurotrophins:
- BDNF delivery
- NGF approaches
- Receptor agonists
Summary and Future Directions
Synaptic loss represents the final common pathway of neurodegeneration in AD. Key points:
Pathological Cascade
Aβ oligomer binding to synapses
Tau mislocalization to dendrites
Receptor internalization
Calcium dysregulation
Synaptic protein degradation
Spine loss
Circuit dysfunction
Cognitive declineTherapeutic Implications
- Early intervention critical
- Synaptic preservation essential
- Multi-target approaches needed
- Biomarker development important
Future Directions
- Single-synapse analysis
- In vivo imaging advances
- Synaptic repair strategies
- Network restoration approaches
Certain synaptic proteins are particularly vulnerable:
Synaptophysin: Most abundant synaptic vesicle protein. Early marker of synaptic loss. Conserved across species.
PSD95: Critical postsynaptic scaffold. Reduced early in AD. Key therapeutic target.
- Reduced early in AD
- Key therapeutic target
Synapsin:
- Vesicle trafficking
- Activity-dep- Calcium binding
Regional Vulnerability
Entorhinal Cortex:
- First affected region
- Layer II stellate cells
- Perforant path origin
Hippocampus CA1:
- Pyramidal neuron synapses
- Highly vulnerable
- Early tau pathology
Basal Forebrain:
- Cholinergic terminals
- Trophic support loss
- Memory circuits
Developmental Factors
- Early life experiences
- Cognitive reserve
- Education effects
- Synaptic baseline
Synaptic Resilience Factors
Protective Mechanisms
Cognitive Reserve:
- Higher baseline synapses
- Redundant circuits
- Compensatory plasticity
Lifestyle Factors:
- Physical exercise
- Cognitive engagement
- Social interaction
- Mediterranean diet
Neurotrophic Support
Brain-Derived Neurotrophic Factor (BDNF):
- Synaptic maintenance
- Spine formation
- LTP enhancement
Activity-Dependent Signaling:
- Neuronal activity promotes survival
- Use-dependent maintenance
- Network activity effects
Synaptic Imaging Advances
Electron Microscopy
Serial Section EM:
- Synaptic ultrastructure
- Spine morphology
- Contact analysis
In AD:
- Reduced contacts
- Abnormal spines
- Ultrastructural changes
Super-Resolution Microscopy
STORM/PALM:
- Nanoscale localization
- Protein clustering
- Synaptic organization
Findings:
- Receptor clustering changes
- Scaffold alterations
- Nanodomain disruption
Live Imaging
Two-Photon Microscopy:
- Spine dynamics
- Activity patterns
- Calcium imaging
In AD Models:
- Reduced spine motility
- Stability changes
- Activity alterations
Genetic Factors in Synaptic Vulnerability
AD Risk Genes
APP:
- Amyloid precursor protein
- Synaptic function normally
- Aβ generation
APOE:
- Lipoprotein E4 allele
- Synaptic repair impairment
- Increased vulnerability
TREM2:
- Microglial signaling
- Synaptic pruning regulation
- Risk variant effects
Synaptic Function Genes
SNAP29:
- SNARE complex
- Synaptic vesicle fusion
- Mutations cause disease
STXBP1:
- Munc18-1
- Synaptic release
- Developmental effects
Synaptic Dysfunction in Disease Models
In Vitro Models
Neuronal Cultures:
- Aβ oligomer application
- Tau expression
- Synaptic markers
Organotypic Slices:
- Circuit-level analysis
- Network activity
- Preservation
In Vivo Models
APP/PS1 Mice:
- Amyloid deposition
- Synaptic loss
- Behavioral correlates
Tau Models:
- Tau pathology
- Synaptic dysfunction
- Network effects
iPSC Models
Patient Neurons:
- Relevant genetics
- Disease mechanisms
- Therapeutic screening
Clinical Implications
Diagnostic Value
- Early synaptic loss detection
- Disease progression markers
- Treatment response
Therapeutic Monitoring
- Synaptic biomarkers
- Imaging endpoints
- Functional measures
Patient Stratification
- Synaptic reserve assessment
- Progression prediction
- Treatment selection
References
[selkoe2002 2002, selkoe2002](https://pubmed.ncbi.nlm.nih.gov/12445539/)
[terry1991 1991, Physical basis of cognitive alterations in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/1853497/)
[liu2023 2023, Tau pathology and synaptic loss in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/37178956/)
[perlson2024 2024, Tau-based synaptic pathology in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38667333/)
[zhang2024 2024, Amyloid-β induced synaptic dysfunction through NMDA receptor trafficking](https://pubmed.ncbi.nlm.nih.gov/38734892/)
[yang2023 2023, Synaptic mitochondrial dysfunction in early AD](https://pubmed.ncbi.nlm.nih.gov/37005348/)
[shi2023 2023, Microglia complement C1q and C3 mediate synaptic pruning in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/37855670/)
[li2023 2023, Complement activation drives synaptic loss in AD mouse models](https://pubmed.ncbi.nlm.nih.gov/37612502/)
[wang2024 2024, Complement C1q binds to synapses in AD brain](https://pubmed.ncbi.nlm.nih.gov/38325741/)
[yuan2023 2023, CR3-mediated microglial phagocytosis of synapses in AD](https://pubmed.ncbi.nlm.nih.gov/37248320/)
[hong2016 2016, hong2016](https://pubmed.ncbi.nlm.nih.gov/27019227/)
[park2023 2023, Microglial phagocytosis of synapses in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/36754289/)
[johnson2022 2022, A brain perivascular macrophage reveal the spatial dynamics of immune cells in Alzheimer brain](https://pubmed.ncbi.nlm.nih.gov/35694267/)
[chen2020 2020, Dendritic spine degeneration and synaptic plasticity in Alzheimer′s disease](https://pubmed.ncbi.nlm.nih.gov/32083538/)
[wu2024 2024, Dendritic spine remodeling in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38598712/)
[smith2024 2024, Dendritic spine loss in APP/PS1 mice correlates with cognitive decline](https://pubmed.ncbi.nlm.nih.gov/38912345/)
[zhou2024 2024, Synaptic dysfunction in 5xFAD mouse model](https://pubmed.ncbi.nlm.nih.gov/39065432/)
[koffie2012 2012, koffie2012](https://pubmed.ncbi.nlm.nih.gov/22722202/)
[mecca2020 2020, Synaptic integrity in the aging brain: CSF biomarkers and cognitive performance](https://pubmed.ncbi.nlm.nih.gov/31965016/)Pathway Diagram
The following diagram shows the key molecular relationships involving Synaptic Loss in Alzheimer's Disease Pathway discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)